Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 8/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121577 | 0.92 | HDAC6 (0.44) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3127930 | 0.91 | HDAC6 (0.46) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3121370 | 0.91 | HDAC6 (0.52) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3117096 | 0.91 | HDAC6 (0.56) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL5057773 | 0.90 | HDAC6 (0.43) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3119210 | 0.89 | HDAC6 (0.50) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL5062923 | 0.88 | HDAC6 (0.42) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3117065 | 0.87 | MAPT (0.50) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3124799 | 0.87 | HDAC6 (0.49) | LTB4R2HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL3119193 | 0.86 | HDAC6 (0.48) | LTB4R2HDAC6HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | MALT1, SLC10A2, LCP2 | LTB4R2 66/4885HDAC6 1723/4885HDAC1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.